Near-term strategies for biotech drug developers facing shifting healthcare dynamics
A dynamic convergence of economic, legislative, scientific, and technological influences is molding the future of the healthcare industry – with implications for biotech companies. Healthcare environments are becoming increasingly complex as drug developers increasingly make the transition to next-generation therapeutics, driving demand for clinical innovation. Against this backdrop, the industry continues to pioneer new approaches to engaging with patients, clinical trial teams, and healthcare providers. During a recent panel discussion, Goldman Sachs and Parexel shared perspectives on emerging trends and high-level developments to help biotechs plan their short- and near-term strategies.
Get more insights from our recent panel discussion with Goldman Sachs, entitled “Decoding Healthcare’s Future: A comprehensive analysis of investment, clinical research and regulatory dynamics.”
The views and opinions expressed by the authors are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs, or Parexel, for you to take any action.
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021